Effects of nitric oxide synthase inhibition on dexmedetomidine-induced vasoconstriction in healthy human volunteers

British Journal of Anaesthesia

Volumn 102, Issue 1, 2009, Pages 38-46

  Snapir, A ^a   Talke, P ^b   Posti, J ^a   Huiku, M ^c   Kentala, E ^d   Scheinin, M ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GE Healthcare Finland Oy   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Muscle vascular, pharmacology, responses; Pharmacology, dexmedetomidine, nitric oxide; Sympathetic nervous system, dexmedetomidine

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR; DEXMEDETOMIDINE; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE; SODIUM CHLORIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MECHANISM; ENZYME INHIBITION; FINGER BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; VASOCONSTRICTION;

EID: 57349105852     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aen316     Document Type: Article

References (23)

1. Talke PO, Lobo E, Brown R. Systemically administered alpha2-agonist- induced peripheral vasoconstriction in humans. Anesthesiology 2003; 99: 65-70
2. Figueroa XF, Poblete MI, Boric MP, Mendizabal VE, Adler-Graschinsky E, Huidobro-Toro JP. Clonidine-induced nitric oxide-dependent vasorelaxation mediated by endothelial alpha(2)-adrenoceptor activation. Br J Pharmacol 2001; 134: 957-68
3. Gerlach AT, Dasta JF. Dexmedetomidine: an updated review. Ann Pharmacother 2007; 41: 245-52
4. McCutcheon CA, Orme RM, Scott DA, Davies MJ, McGlade DP. A comparison of dexmedetomidine versus conventional therapy for sedation and hemodynamic control during carotid endarterectomy performed under regional anesthesia. Anesth Analg 2006; 102: 668-75
5. Ramsay MA, Luterman DL. Dexmedetomidine as a total intravenous anesthetic agent. Anesthesiology 2004; 101: 787-90
6. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000; 93: 382-94
7. Snapir A, Posti J, Kentala E, et al. Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects. Anesthesiology 2006; 105: 902-10
8. Lembo G, Iaccarino G, Vecchione C, et al. Insulin modulation of an endothelial nitric oxide component present in the alpha2- and beta-adrenergic responses in human forearm. J Clin Invest 1997; 100: 2007-14
9. Bruck H, Gossl M, Spitthover R, et al. The nitric oxide synthase inhibitor L-NMMA potentiates noradrenaline-induced vasoconstriction: effects of the alpha2-receptor antagonist yohimbine. J Hypertens 2001; 19: 907-11
10. Muszkat M, Sofowora GG, Wood AJ, Stein CM. Alpha2-adrenergic receptor-induced vascular constriction in blacks and whites. Hypertension 2004; 43: 31-5
11. Muszkat M, Sofowora GG, Xie HG, Wood AJ, Stein CM. Alpha2B adrenergic receptor 301-303 deletion polymorphism and vascular alpha2 adrenergic receptor response. Pharmacogenet Genomics 2005; 15: 23-8
12. Aellig WH. Clinical pharmacology, physiology and pathophysiology of superficial veins - 1. Br J Clin Pharmacol 1994; 38: 181-96
13. Alradi AO, Carruthers SG. Evaluation and application of the linear variable differential transformer technique for the assessment of human dorsal hand vein alpha-receptor activity. Clin Pharmacol Ther 1985; 38: 495-502
14. Vallance P, Collier J, Moncada S. Nitric oxide synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivo. Cardiovasc Res 1989; 23: 1053-7
15. Scheinin M, Karhuvaara S, Ojala-Karlsson P, Kallio A, Koulu M. Plasma 3,4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are insensitive indicators of alpha-2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers. Life Sci 1991; 49: 75-84
16. Coughlan MG, Lee JG, Bosnjak ZJ, Schmeling WT, Kampine JP, Warltier DC. Direct coronary and cerebral vascular responses to dexmedetomidine. Significance of endogenous nitric oxide synthesis. Anesthesiology 1992; 77: 998-1006
17. McPherson RW, Kirsch JR, Traystman RJ. Inhibition of nitric oxide synthase does not affect alpha2-adrenergic-mediated cerebral vasoconstriction. Anesth Analg 1994; 78: 67-72
18. Sunano S, Li-Bo Z, Matsuda K, Sekiguchi F, Watanabe H, Shimamura K. Endothelium-dependent relaxation by alpha2-adrenoceptor agonists in spontaneously hypertensive rat aorta. J Cardiovasc Pharmacol 1996; 27: 733-9
19. Bockman CS, Gonzalez-Cabrera I, Abel PW. Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats. J Pharmacol Exp Ther 1996; 278: 1235-43
20. Angelini G, Ketzler JT, Coursin DB. The effects of alpha2-adrenoceptor agonists on circulation and respiration. Best Pract Res Clin Anaesthesiol 2000; 14: 449-58
21. Joshi MS, Ferguson TB, Jr, Johnson FK, Johnson RA, Parthasarathy S, Lancaster JR, Jr. Receptor-mediated activation of nitric oxide synthesis by arginine in endothelial cells. Proc Natl Acad Sci USA 2007; 104: 9982-7
22. Haefeli WE, Srivastava N, Kongpatanakul S, Blaschke TF, Hoffman BB. Lack of role of endothelium-derived relaxing factor in effects of alpha-adrenergic agonists in cutaneous veins in humans. Am J Physiol 1993; 264: H364-9
23. King D, Etzel JP, Chopra S, et al. Human response to alpha2-adrenergic agonist stimulation studied in an isolated vascular bed in vivo: biphasic influence of dose, age, gender, and receptor genotype. Clin Pharmacol Ther 2005; 77: 388-403